SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Genaissance Pharmaceuticals (GNSC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jim Oravetz who started this subject9/11/2003 8:16:40 AM
From: nigel bates   of 183
 
Genaissance Pharmaceuticals and AstraZeneca Sign Pharmacogenomics Based Agreement

NEW HAVEN, Conn., Sept. 11 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) today announced that it has entered into a licensing agreement with AstraZeneca PLC (NYSE: AZN - News) to utilize information generated from Genaissance's Statin Response Examined by Genetic Haplotype Markers (STRENGTH) study. Under the terms of the agreement, AstraZeneca will receive non-exclusive access to the STRENGTH study database for research purposes for a limited period. This marks the second commercialization agreement related to the proprietary data generated in Genaissance's STRENGTH study.

"We are pleased to enter into this new agreement with AstraZeneca," said Kevin Rakin, President and CEO of Genaissance. "Such agreements demonstrate our continued effort to commercialize and build on our internal programs such as STRENGTH."

The licensing arrangement is focused on proprietary data generated in the STRENGTH study. This study of more than 400 patients demonstrated that gene variations are associated with response to treatment with the statin class of drugs. Conducted over 16 weeks, the STRENGTH study prospectively analyzed for an association between an individual's genetics and the clinical effectiveness of three statins (atorvastatin, pravastatin and simvastatin) in reducing LDL- cholesterol. Initial results of this study were presented at the 52nd Annual American College of Cardiology Scientific Session in March 2003....
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News